Congestive Heart Failure Drugs Market – Size, Share, Outlook

10
newspaper-412452_1280

Congestive heart failure commonly called as heart failure is a medical condition that affects pumping ability of heart muscle. Certain medical conditions such as narrowing of arteries of the heart or high blood pressure gradually makes the heart too weak and stiff to fill and pump efficiently. Some symptoms of heart failure are shortness of breath while lying down or while exerting yourself, weakness, fatigue, swelling in legs, feet and ankles, irregular and rapid heartbeat, decrease in ability to exercise, persistent cough or wheezing with pink or white blood tinged phlegm, increased urination at night, swelling of abdomen, rapid weight gain due to fluid retention, lack of appetite, nausea, difficulty in concentrating, decreased alertness, severe shortness of breath and coughing up pink, and foamy mucus.

Click To Continue Reading :

https://www.coherentmarketinsights.com/ongoing-insight/congestive-heart-failure-drugs-market-1839 

There are four types of heart failure left-sided heart failure, right-sided heart failure, systolic heart failure and diastolic heart failure. Risk factors that can cause heart failure are high blood pressure, coronary artery disease, diabetes, sleep apnea, obesity, virus, alcohol use, hypertension and irregular heartbeat. Lifestyle changes can help in prevention of heart failure by reducing and managing stress, maintaining a healthy weight, eating healthy food, staying physically fit and active, controlling blood pressure, and diabetes.

Congestive Heart Failure Drugs Market Drivers:-

Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these drugs are used to treat congestive heart failure. Tolvaptan sponsored by Otsuka pharmaceuticals Co., Ltd was in phase 3 clinical trials in 2016, this drug is indicated for treatment of heart failure in children.

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/1839

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org